secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0001104659-24-078172
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron expects $24M IPR&D charge in Q2 2024, ~$0.18 EPS hit
--------------------------------------------------------------

- Estimated pre-tax acquired IPR&D charge of ~$24 million for Q2 2024.
- Charge expected to negatively impact GAAP and non-GAAP EPS by ~$0.18 per diluted share.
- Charge relates to up-front payments and equity premium on collaboration and licensing deals.
- Results are preliminary and subject to financial close procedures; actual may vary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465924078172/0001104659-24-078172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465924078172/tm2418837d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-078172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer